Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 330 (Eluvixtamab) in Myeloid Malignancies
NCT02520427Phase 1Terminated
- Sponsor
- Amgen
- Start
- Aug 2015
- Primary completion
- Jan 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of eluvixtamab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (5 arms), sponsored by Amgen. Primary endpoints: Dose-limiting Toxicity and Treatment-emergent Adverse Event. Started Aug 2015; status: terminated.
02
Drugs
eluvixtamab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02520427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02520427.